In this study, we identified
MAGEL2 truncating variants in six of 105 (5.7%) patients initially suspected to have PWS, but excluded following specific genetic testing. These variants, including two novel variants, were centrally localized to a previously reported hotspot at amino acids 587–666 [
5,
9]. To clarify how SYS and PWS share clinical features, we examined the clinical presentation of our patients with SYS. The major symptoms overlapping of PWS were hypotonia, poor sucking and developmental delay confirmed in all patients. We also found that four of the six (66.7%) patients in our cohort showed hypopigmentation, which is commonly seen in PWS but not previously reported in SYS. Hypopigmentation is thought to be caused by a dysfunction of
OCA2 or
GABRB3 [
21], not by
MAGEL2, and thus it was not expected. Yet, since our cohort was initially suspected of having PWS, an inclusion bias may be present. It was recently reported that Chitayat-Hall syndrome was also caused by pathogenic variants in
MAGEL2 [
12,
14]. GH deficiency, which is a characteristic of this syndrome, was found in all three cases in whom GH was evaluated. Therefore, GH deficiency should also be assessed in SYS. Interestingly, in a recent paper, Patak et al. produced a review of their cases and a systematic review and found no clinical or genetic differences between SYS and Chitayat–Hall syndrome [
14]. In addition, arthrogryposis, which is not found in PWS, was confirmed in all patients as previously reported [
3,
5‐
10]. Many of the intellectual disabilities confirmed in this cohort were severe. No patients acquired meaningful words. The mean intelligence quotient (IQ) of PWS patients is 60–70 [
22], therefore intellectual disability in SYS patients is significantly more severe than PWS patients. However, Patients 1, 2, 3 and 6 may have been affected by neurological deterioration due to encephalopathy-like episodes. Interestingly, four of the six patients had an episode of neurological deterioration following febrile illness. Although McCarthy et al. reported that 67% of patients with SYS showed temperature instability [
9], no episodes of neurological deterioration have been reported. In Japan, the prevalence of febrile seizures and acute encephalopathy is high [
23,
24], which may be associated with the high prevalence of encephalopathy-like episodes in this population. In addition, because post-febrile regression is difficult to identify, particularly in patients with severe intellectual disabilities, some patients may have been overlooked. Therefore, careful observation should be performed for patients with SYS during febrile illness. Although it was reported that SYS patients have a higher prevalence of ASD [
3,
5,
9], this could not be evaluated due to the severe intellectual disability in most of our patients. Previous studies report that among adolescent patients with SYS, the proportion of those who presented with hyperphagia and obesity was low, unlike that of patients with PWS, and many of those presented with ASD [
9,
14]. In our study, it was difficult to evaluate patients in these respects because we could only observe two patients until puberty; however, we identified some patients without hyperphagia, obesity, or the personality characteristic of PWS. Overall, our study finds that symptoms of SYS are distinct from, and more severe than, those of PWS.
Next, a genotype–phenotype correlation is discussed. Previous reports have mentioned that c.1996dupC is the most common variant, which is more severe than other variants (e.g., frequencies of arthrogryposis, tube feeding, and respiratory dysfunction) [
9,
14]. In our study, however, Patient 4 (c.1996dupC) had a history of tube feeding during infancy, but did not show respiratory dysfunction, indicating that the patient’s condition was comparable to that of other patients at least by the age of 6 years.
Buiting et al. [
17] reported a 3-year-old boy with a paternally inherited approximately 3.9 Mb deletion that spanned
MAGEL2 but not the
SNORD116 cluster. The patient showed mild motor delay, which appears to be different to the SYS phenotype. Therefore, the truncated variants of
MAGEL2 identified in SYS may cause different phenotypes to a complete deletion of
MAGEL2, which is likely to represent loss of function. However, it should be noted that the 3.9 Mb deletion may not represent loss of function of
MAGEL2 because it could disturb proper expression of some other genes. This can only be established however, once more cases with a complete deletion of
MAGEL2 are reported. It should also be noted that almost only truncated variants but only one missense variant have been identified in
MAGEL2 [
14]. If loss of function is the major pathomechanism, a missense variant, especially at a functional domain, would be expected. As
MAGEL2 is a single exon gene, nonsense-mediated mRNA decay is not induced. Therefore, truncating variants in
MAGEL2 may result in abnormal truncated protein products through a gain-of-function mechanism. Although several articles have raised the possibility of a dominant negative mechanism [
5,
15], it seems that a gain-of-function mechanism is the most likely pathological mechanism because there is no proof that MAGEL2 forms multimers.
MAGEL2 belongs to the MAGE family proteins that were initially identified as tumor-specific antigens [
25]. Proteins encoded by the MAGE gene family, with approximately 40 unique members in humans, share the MAGE homology domain that mediates protein-protein interaction [
25,
26]. MAGEL2 is known to bind and to enhance the activity of the TRIM27 E3 RING ubiquitin ligase. The MAGEL2-USP7-TRIM27 (MUST) complex plays an important role in a cellular process that recycles membrane proteins from endosomes through the retromer sorting pathway [
15,
27,
28]. Thus, dysregulation of this pathway may be associated with the pathogenesis of SYS. Indeed, retromer has been implicated in several neurodegenerative disorders in humans, including Alzheimer’s and Parkinson’s disease [
29,
30].